Treatment- Melanoma- Single Injection PV-10
Single Injection May Revolutionize
Melanoma Treatment
Aug. 22, 2013 — A new study at Moffitt Cancer Center could
offer hope to people with melanoma, the deadliest form of skin cancer.
Researchers are investigating whether
an injectable
known as PV-10 can shrink
tumors and reduce the spread of cancer. PV-10 is a solution developed
from Rose Bengal, a water-soluble
dye commonly used to stain damaged cells in the eye. Early clinical
trials show PV-10 can
boost immune response in melanoma tumors, as well as the blood stream.
"Various injection therapies for melanoma have been
examined over the past 40 years, but few have shown the promising results we
are seeing with PV-10," said Shari Pilon-Thomas, Ph.D., assistant member
of Moffitt's Immunology Program.
In the initial study, researchers injected a single dose of PV-10 into mice with
melanoma. The result was a significant reduction in the skin cancer lesions, as well as a
sizable reduction in
melanoma tumors that had spread to the lungs. The researchers said the
dye solution appeared to produce
a robust anti-tumor immune response and may be safer than existing
immunological agents.
"We are currently in the middle of our first human
clinical trial of PV-10 for
advanced melanoma patients. In addition to monitoring the response of
injected melanoma tumors, we are also measuring the boost in the anti-tumor immune cells of
patients after injection," explained Amod A. Sarnaik, M.D.,
assistant member of Moffitt's Cutaneous Oncology Program.
The initial study appears in PLOS ONE. It was supported by a
sponsored research agreement with Provectus Pharmaceuticals, Inc., developer of
PV-10.
Share this story on Facebook
No comments:
Post a Comment